ReviewCurrent research in pharmacology and drug discovery2021
Unmet needs in inflammatory bowel disease.
Review in Current research in pharmacology and drug discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- The role of GLP-1 receptor agonists in IBD-related surgery and IBD-related complications of inflammatory bowel disease among patients with metabolic comorbidities: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Dose Escalation Patterns of Advanced Therapies in Crohn's Disease and Ulcerative Colitis: A Systematic Literature Review.Advances in therapy · 2023Pooled it
- Safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of olamkicept: Results from randomized, placebo-controlled, first-in-human phase I trials.Clinical and translational science · 2024Trial
- Clinical characterization and healthcare burden of difficult-to-treat inflammatory bowel disease in Latin America: a real-world registry-based study.Crohn's & colitis 360 · 2026Article
- Knowledge Gaps, Treatment Preferences, and Unmet Clinical Needs Among Patients With Inflammatory Bowel Disease: A Cross-Sectional Study.The Kaohsiung journal of medical sciences · 2026Article
- Engineering Nanomaterial Platform for Inflammatory Bowel Disease: Three-Dimensional Integration of Delivery Mechanism, Therapeutic Drug Delivery and Intelligent Material Design.International journal of nanomedicine · 2026Review
- Combining Network Pharmacology, Molecular Docking, and Integrative Studies to Explore the Mechanism ofFood science & nutrition · 2025Article
- Efficacy and Safety of Ustekinumab in Treatment of Ulcerative Colitis: A Systematic Review.Cureus · 2025Review
- Unmet health-related needs in patients with Crohn's disease in Belgium: a mixed-methods study.Archives of public health = Archives belges de sante publique · 2025Article
- Unmet Healthcare Needs Among People with Inflammatory Bowel Disease: A Canadian Cross-Sectional Population-Representative Study.Digestive diseases and sciences · 2025Article
- Addressing the Critical Gap in Biological Therapies for Inflammatory Bowel Disease in Syria.Avicenna journal of medicine · 2025Article
- Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: Results From a Large Survey Across Seven European Countries Using a Discrete Choice Experiment.Inflammatory bowel diseases · 2024Article
- Exploring Pyroptosis-related Signature Genes and Potential Drugs in Ulcerative Colitis by Transcriptome Data and Animal Experimental Validation.Inflammation · 2024Article
- Development and validation of a scale to measure the care needs of Crohn's disease patients: a mixed-methods study.BMC nursing · 2024Article
- Modelling Treatment Sequences in Immunology: Optimizing Patient Outcomes.Advances in therapy · 2024Article
- Optimization of Selectivity and Pharmacokinetic Properties of Salt-Inducible Kinase Inhibitors that Led to the Discovery of Pan-SIK Inhibitor GLPG3312.Journal of medicinal chemistry · 2024Article
- Effectiveness of Partial Enteral Nutrition as Add-On to Biologics in Patients With Refractory and Difficult-to-Treat Crohn's Disease: A Pilot Study.Crohn's & colitis 360 · 2024Article
- Insights into disability and psycho-social care of patients with inflammatory bowel disease.Frontiers in medicine · 2024Review
- Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease.Frontiers in medicine · 2023Review
- Pretreatment with IPA ameliorates colitis in mice: Colon transcriptome and fecal 16S amplicon profiling.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the recent developments in the diagnosis and management of inflammatory bowel diseases (IBD), patients still suffer from disabling bowel symptoms and significant disease complications and many questions remain to improve their care. IBD is a chronic disease, whose management could be divided into the five different stages of chronic diseases, ranging from the pre-treatment evaluation phase to the induction therapy, maintenance therapy, monitor and re-establishment of control and the cessation of the disease. Reconciling these phases with the current unmet needs in IBD could help tailor priorities for research. In this review, some of the unanswered questions in the management of both Crohn's Disease and Ulcerative Colitis will be addressed, by following this paradigm of chronic diseases' management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.